What Does Bangladesh’s Extended LDC Status Mean for Access to Medicine?

Image from here.

Bangladesh was originally set to graduate from the United Nations’ “Least Developed Country” (LDC) category this month, having met all three graduation thresholds. However, following an extension request from the Bangladesh Government, the UN General Assembly last month passed a resolution deferring its graduation to 2029.

The UN currently classifies Bangladesh as a “LDC”. As LDCs reach a level of development, they graduate to the category of “Developing Countries”. The UN Committee for Development Policy (CDP) assesses LDC graduation every three years. It looks at certain factors that we won’t get into for this blog post (see here broadly).

As the 2026 deferral shows, graduation dates are not rigid in nature, so we also don’t know if 2029 will see their graduation either. But why are we talking about this at all?

As per Article 66.1 of the WTO TRIPS Agreement, LDC Members of the WTO get a general transition period, exempting them from implementing most of the TRIPS Agreement, until 1st July 2034, as well as a specific pharma sector exemption until 1st January 2033. Bangladesh uses the TRIPS LDC exemptions to suspend product patent protection for pharmaceuticals (Section 6(2) of the Bangladesh Patent Act 2023) while allowing process patent protection. This allows the country’s local firms to manufacture and sell generic versions without requiring permission through an expensive voluntary license from a patentee or a difficult-to-obtain compulsory license issued by the government. This, along with policies like the Drug (Control) Ordinance 1982, has helped the Bangladesh pharma sector to grow.

More pertinently, Bangladesh, as an LDC, can also legally export the generic drugs, including cancer medicines such as Osimertinib, Ibrutinib and antivirals like Remdesivir, produced under the TRIPS LDC exemptions to other LDCs, and even to non-LDC countries where the drug is either not patented or where the government of countries importing the drug has issued a compulsory license under the TRIPS flexibilities.

In the Indian A2M context, unlike Bangladesh, India is in the “Developing Country” category and has product patents for pharmaceuticals since 2005 to comply with the TRIPS Agreement. However, public health levers exist in law. Section 107A(b) of the Patents Act, 1970 is one such provision, which allows for importing patented medicines (products) without the patentee’s permission, so long as the supplier is duly authorised under the law.

For example, let’s take X, a breast cancer medicine that is under an active Indian product patent held by an originator company, making it illegal to manufacture generic versions of X without a voluntary or compulsory license in India. Now, let’s say a pharma manufacturer in Bangladesh produces a (non-patented due to LDC suspension of patent protection) version of X. Under a plain reading of Section 107A(b), an importer in India (after getting drug regulatory import clearance from CDSCO) can import that medicine from this manufacturer in Bangladesh as it is “duly authorised under the law”, i.e., under Bangladesh’s LDC exemption, and importantly, the importer does not separately require the authorisation of the patent holder.

This was in fact recently upheld in K K Bansal v. Koninklijke Philips Electronics Nv (2026), where a Division Bench at the DHC held that post the 2005 amendment to S. 107A(b), the defendant doesn’t need to prove authorisation by the patentee. Being duly authorised under the law is enough. While the decision does not expressly say authorised under whose law, the Court treated the Chinese sellers as authorised in practice, pointing towards the foreign (seller’s) jurisdiction. (Though to note: the K K Bansal ruling is currently under appeal before the Apex Court.)

Aside from its domestic needs, Bangladesh’s local firms are supplying essential life-saving medicines across 151 countries in Europe, America, the Middle East, and Central Asia, including the US, the UK, Germany, etc. This includes governments, NGOs, patient groups, and individuals who look to Bangladesh for exporting essential medicines such as cancer drugs, procuring which would often otherwise make patients and their entire families go into debt because of how expensive they are.

For example, in 2025, Just Treatment, a patient group, along with Third World Network and the global campaign Right to Breathe, worked with Beximco, a Bangladeshi firm, to make a generic version of Trikafta, a cystic fibrosis medicine, accessible for patients in various countries.  The generic medicine is priced at $6,375 (children) / $12,750 (adults) a year, as compared to the patented medicine amount, which comes to approximately $370,000 a year, according to Vertex’s price tag.

Together, these examples show why Bangladesh’s use of the TRIPS waiver as an LDC fits into the larger picture of the Access to Medicine (A2M) movement. A premature exit would have abruptly clipped the flexibilities under Article 66.1 of the TRIPS Agreement and constrained generic export pipelines relied upon by healthcare systems across the Global South.

Grateful to Swaraj Barooah for the invaluable guidance on this post, helping trace how Bangladesh’s LDC exemption connects with Section 107A(b).

Read More